植耀輝: 貿談有進展美股上揚 港股27,000點關口阻力大
耀才證券研究部總監植耀輝稱,美股上周五(25日)早段雖受企業業績拖累,但其後受中美貿易談判進展理想消息支持上揚,道指上升152點或0.57%,收報26,958點,標普500指數亦升12點或0.41%,收報3,022點,納指則升57點或0.7%,收報8,243點。
雖然中美貿易談判似有正面消息,但投資市場本周焦點多多,聯儲局議息會議、內地四中全會以至大型企業第三季業績表現皆會對後市有一定影響,因此預期大市將繼續維持拉鋸格局,並繼續於26,000至27,000點水平徘徊。另外今日亞盛醫藥(06855.HK)上市,暗盤表現相當不俗,不過若今早大幅高開,則不建議大家高追,雖然此類生物科技股新藥一旦研發成功潛在商機可能十分之高,但現階段卻仍充滿眾多不確定性,故即使打算高追的話,亦宜先訂止蝕止賺策略。
(筆者為證監會持牌人,並未持有相關股份)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.